Physician profile
Dawn Blackshear
NPI 1467976423
$3,470.55
in general payments reported to CMS, 2019-2025
47 companies · $3,262 in 2025
The $3,262 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $110 · 2024: $98.38 · 2025: $3,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979 · Education: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.60 |
| Education | $491.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $240.09 | 2025 | |
| Myriad Genetic Laboratories, INC. | $237.21 | 2023-2025 | Myrisk |
| Astellas Pharma US INC | $233.18 | 2025 | Xtandi, Vyloy |
| Janssen Biotech, INC. | $196.02 | 2025 | Erleada, Rybrevant, Akeega |
| Daiichi Sankyo INC. | $194.19 | 2025 | Enhertu, Datroway |
| Sobi, INC | $174.69 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $153.73 | 2025 | Onivyde |
| Exelixis INC. | $118.58 | 2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $111.17 | 2025 | Vpriv, Iclusig |
| Seagen INC. | $99.99 | 2025 | |
| Glaxosmithkline, LLC. | $96.52 | 2025 | Zejula, Jemperli, Ojjaara |
| Celgene Corporation | $92.12 | 2025 | Reblozyl |
| Array Biopharma INC | $90.89 | 2025 | Mektovi, Braftovi, Lorbrena |
| Pfizer INC. | $85.15 | 2025 | |
| Incyte Corporation | $84.39 | 2025 | Jakafi, Monjuvi, Zynyz |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Blackshear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.